Fewer than 10 GCC haematologists, concentrated at seven institutions across three cities, manage the region's confirmed PNH caseload, and 5-8 of them decide whether a new agent gets adopted.
GCC PNH expertise concentrates around a small number of specialist centres, not a broad regional field. Confirmed PNH management sits at seven institutions across three cities: King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Riyadh, which anchors the region's largest published PNH cohort at roughly 40 patients, King Abdulaziz Medical City (KAMC) in both Riyadh and Jeddah, American Hospital Dubai, Rashid Hospital in Dubai, and Sheikh Shakhbout Medical City together with AUH in Abu Dhabi. Fewer than 10 haematologists across this network manage the confirmed GCC PNH caseload, itself only around 400 of an estimated 2,000 to 3,000 patient pool given the region's FLAER-testing bottleneck. That concentration is not incidental; NPHC's prior-authorisation criteria route every confirmed diagnosis through these same institutions. Our KOL Universe gate (K1) starts by mapping exactly this seven-institution structure before any single physician is scored.
That structure changes how AXLRx tiers influence in the GCC. A haematologist at KFSH&RC, the region's largest published cohort and the institution most likely to shape NPHC's own prior-authorisation posture, carries different scientific weight than one at a lower-volume peripheral centre, and our Tier Classification gate (K2) scores that distinction directly. Only 5 to 8 physicians across this network function as genuine adoption gatekeepers, the practitioners whose prescribing decisions determine whether a new complement inhibitor gains real GCC uptake once SFDA registration clears. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live publication records and institutional affiliations, then marked Verified, Industry benchmark, or Requires client validation.
The GCC PNH institution network, seven centres across three cities
| Institution | City | Role in Network |
|---|---|---|
| King Faisal Specialist Hospital & Research Centre (KFSH&RC) | Riyadh | Anchor referral centre; largest published GCC PNH cohort (~40 patients) |
| King Abdulaziz Medical City (KAMC) | Riyadh | NPHC-designated haematology centre |
| King Abdulaziz Medical City (KAMC) | Jeddah | NPHC-designated haematology centre |
| American Hospital Dubai | Dubai | Designated treatment centre |
| Rashid Hospital | Dubai | Designated treatment centre |
| Sheikh Shakhbout Medical City | Abu Dhabi | Designated treatment centre |
| AUH | Abu Dhabi | Designated treatment centre |
Sources: NPHC Pharmaceutical Benefits Committee review process documentation; KFSH&RC haematology department published case series 2019-2023; SNRHD 2022; GCC haematology society PNH case registry.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The seven-institution structure across Riyadh, Jeddah, Dubai, and Abu Dhabi
- physician concentration as a KOL-tiering signal
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- KFSH&RC cohort authorship and NPHC prior-authorisation-role weighting
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live publication and institutional-affiliation cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the seven-institution GCC network case before the rest of the workbook is built out
- Every GCC PNH KOL sized and sourced from publication and institutional-affiliation data
- The seven-institution network across Riyadh, Jeddah, Dubai, and Abu Dhabi as the sizing anchor
- Universe boundaries: who counts as a KOL versus a high-volume prescriber
- Scientific-influence scoring across KFSH&RC cohort authorship and NPHC prior-authorisation role
- What separates a Tier 1 KOL from a high-volume community prescriber
- Influence inputs: published cohort authorship, NPHC-facing institutional role, FLAER-testing capability
- Cross-checked against independent publication and citation data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
- Territory-to-KOL coverage map across Riyadh, Jeddah, Dubai, and Abu Dhabi
- Where current MSL deployment has gaps across the remaining GCC states
- Multi-market reach for KOLs active beyond Saudi Arabia, across the wider GCC
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live publication records and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.
GCC PNH KOL sources: KFSH&RC haematology department published case series; NPHC Pharmaceutical Benefits Committee review process documentation; SNRHD 2022; and the institutional affiliations named in those publications.
- Institution list and KFSH&RC cohort size verified against KFSH&RC haematology department published case series 2019-2023
- Confirmed-case and haematologist-concentration figures verified against SNRHD 2022 and NPHC Pharmaceutical Benefits Committee documentation
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC PNH specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.